A Review of Hormone-Based Therapies to Treat Adult Acne Vulgaris in Women

    March 2017 in “ International Journal of Women's Dermatology ”
    Megha Trivedi, Kanade Shinkai, Jenny E. Murase
    Studysummary This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 9

    1. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome JAMA Dermatology · 2015
    2. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome: The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group Fertility and sterility · 2011
    3. Acne and Systemic Disease Medical Clinics of North America · 2009
    4. Efficacy of an Oral Contraceptive Containing EE 0.03 mg and CMA 2 mg (Belara) in Moderate Acne Resolution: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Contraception · 2009
    5. Hormonal Therapy for Acne Seminars in Cutaneous Medicine and Surgery · 2008
    6. Effects of Two Estroprogestins Containing Ethinylestradiol 30 μg and Drospirenone 3 mg and Ethinylestradiol 30 μg and Chlormadinone 2 mg on Skin and Hormonal Hyperandrogenic Manifestations Gynecological endocrinology · 2008
    7. A Comparison of the Relative Efficacy of Antiandrogens for the Treatment of Acne in Hyperandrogenic Women Clinical Endocrinology · 2002
    8. The Effect of Two Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea PubMed · 2002
    9. Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara®) and EE/LNG (Microgynon®) Dermatology · 2001